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With the mapping of the Human Genome and increasing interest in genetic testing 
and therapies, the potential for ethical problems has increased. Nursing and 
medicine have the ethical responsibility to “do no harm” and to protect the privacy 
of clients. However, our clients may also be family members and descendants of 
those we care for. The purpose of this article is to discuss issues related to genetic 
privacy using a deontological approach and to outline methods to protect clients 
and research participants. 




Ethics and Genetic Privacy 
Introduction 
The field of genetics has made rapid advances in the past ten years. It has been 
enthusiastically embraced and supported by researchers, the public, and the world 
governments as a means to understand, prevent, or treat human disease in the future. 
While the possibilities for ameliorating human suffering are exciting and the benefit of 
scientific advances are great, so are the potential risks involved. A formerly secret or 
unknown code for human development is now becoming accessible. The question of 
how accessible it should be and who will have access, remains. Without an 
understanding and respect for the issues involved, the scientific genetic advances have 
the potential to harm people through lack of truly informed consent or breaches in 
privacy. For this article, issues involving the Human Genome Project and research 
involving genes will be discussed. 
Although genetics has been in the popular news and medical literature in greater 
amounts in the past fifteen years, it is not a new scientific topic. O. Avery, C. MacLeod, 
and M. McCarty identified deoxyribonucleic acid (DNA) in 1944. In 1953 F. Crick and J. 
Watson first described the three-dimensional structure of DNA. M. Nirenberg and H. G. 
Khorana broke the genetic code in 1966 when they found that triplet base pairs of 
messenger ribonucleic acid (mRNA) specified each of the twenty amino acids. 
Recombinant DNA molecules, or the combination of genetic materials from different 
sources through gene splicing, were first produced in 1972 (Lane, 1994). 
During the rapid increase of genetic knowledge, the development of potential ethical 
problems was recognized. By 1975, scientists from around the world adopted guidelines 
for recombinant DNA experiments. In 1989, the Department of Energy (DOE) and the 
National Institute of Health (NIH) formed an Ethical, Legal, and Social Issues (ELSI) 
working group to study the implications of genome research. The working group 
became a branch of the National Center for Human Genome Research (NCHGR) in 
1990 (ELSI, 2000; National Human Genome Research Institute [NHGRI], n.d.). Three to 
five percent of the NHGRI=s and the DOE=s budgets are dedicated to support ELSI 
(ELSI, 2000; NHGRI, 2000). The ELSI program provides the largest amount of federal 
funding for bioethics research with a budget of over $10 million a year (NHGRI, 2000).  
Ethical Concerns Involved with Genetic Research 
Potential ethical concerns are for privacy, confidentiality, and informed consent. Areas 
of concern in privacy and confidentiality are breaches that may lead to discrimination 
and stigmatization of racial groups or individuals in employment or health insurance, or 
whether to inform family members of genetic markers for disease, especially if the 
original participant donor (proband) refuses to release the information. Respect for 
persons issues include: (a) the use of DNA stored samples without consent, (b) 
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autonomy issues such as who owns the data after it is collected and stored and if 
participants and families have the right to choose whether to know about genetic risks 
or not, and (c) the use of genetic information by other researchers especially in for-profit 
ventures. 
Deontological Principles Applied To Genetic Research 
Using a deontological ethical approach and common ethical principles, some of the 
areas of potential harm will be discussed. Deontology, derived from I. Kant’s 
metaphysics of morals, holds that an act is right or moral based on following certain 
principles (Solomon, 1989). It focuses on duties and obligations (Davis, Aroskar, 
Liaschenko, & Drought, 1997). In Fundamental Principles of the Metaphysics of Morals 
(Kant, 1797/1898, T. K. Abbott, Trans., as cited in Solomon, 1989), Kant writes "to be 
beneficent when we can is a duty....the moral worth of the character is brought out 
which is incomparably the highest of all, namely, that he is beneficent, not from 
inclination, but from duty....So act as to treat humanity, whether in thine own person or 
in that of any other, in every case as an end, withal, never as a means only" (Solomon, 
1989, pp. 580-581, 588). Beneficence and non-maleficence, duty to the rights of others, 
and respect for persons are ethical principles that must be upheld to prevent 
unanticipated harm from genetic advances. 
Principals of Respect and Beneficence 
Respect for persons is one of the foundational beliefs of medicine and nursing. This 
belief undergirds the landmark documents used to protect human subjects in research. 
The Belmont Report calls it one of the three basic ethical principles involved in 
research, with beneficence and justice the other two (Sugarman, Mastroianni, & Kahn, 
1998). Autonomy and privacy are two of the issues that are relevant under respect for 
persons. Autonomy is gained through giving the participant the knowledge necessary to 
make a decision. However, problems with autonomous decisions and maintaining 
privacy and confidentiality can occur because genetic material is not just about an 
individual, but about the genetics of related families (HUGO Ethics Committee, 1998; 
Sommerville & English, 1999; Wachbroit, 1993). In that case, the issue becomes who is 
the subject or a patient. The Genetic Privacy Act defines private genetic information as 
information that can identify a person by DNA or other genetic markers in samples 
obtained from an analysis of the individual=s DNA or from the analysis of the DNA of a 
relative, recognizing that genetics isn’t just individual data (Annas, Glantz, & Roche, 
1995). Wachbroit (1993) discusses decision making and confidentiality when the wish 
for privacy and confidentiality on the part of the proband and refusal to notify relatives of 
inheritable disease causes an ethical dilemma. Wachbroit suggests that since the 
information is not just about the individual, the duty is to the family. In situations of 
inheritable diseases, he believes the duty to prevent harm by giving blood relatives who 
are potential parents the information needed to make reproductive choices outweighs 
the individual=s right to privacy. In that case, he argues from a beneficence and non-
malficence view similar to the approach used in public health in preventing the spread of 
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communicable disease to protect a community even if individual confidentiality has to be 
broken. The ethical dilemma occurs because of conflicting rights between the individual 
and the family and future generations. Wachbroit believes the health care provider has 
an ethical obligation to inform the family. However, the Genetic Privacy Act does not 
provide an exception to privacy and confidentiality but believes that the individual 
proband retains the responsibility to notify family members of genetic conditions (Annas 
et al., 1995). 
Principle of Autonomy 
Another issue in viewing people as autonomous is the ability of the person to maintain 
control and ownership of DNA material donated. Researchers frequently argue that 
obtaining consent for each future use of stored DNA samples would be difficult and 
would likely result in less research due to the increased cost and burden on the 
researcher (Troy, 1997). However, landmark documents such as the Helsinki 
Conference, Belmont Report and the Common Rule specify that informed consent must 
be obtained to protect human subjects (Sugarman et al., 1998). The real question is 
whether a consent form that gives researchers specific donor wishes for future use are 
adequate. Present guidelines issued by the Human Genome Organization (HUGO 
Ethics Committee, 1998; Stephenson, 1998) and the Genetics Privacy Act (Annas et al., 
1995) recommend a consent that does give the participant the opportunity to specify 
how they want the sample used. The Genetic Privacy Act assumes the person donating 
the sample retains property rights to the sample (Annas et al., 1995; Troy, 1997). Reilly, 
Boshar, & Holtzman (Reilly et al., 1997) also outlined what they believed to be key 
elements in informing and obtaining consent for genetic studies. Earlier research 
consents frequently did not allow the donor to retain control over the sample. For 
samples obtained prior to the guidelines that allowed the participant to control what 
would be done with the sample, the HUGO Ethics Committee recommends that the 
sample can be used for research if the sample has been anonymized prior to use 
(HUGO Ethics Committee, 1998). 
Principal of Non-maleficence 
Potentially, any tissue or blood sample could be used for genetic studies if it had been 
stored properly (Goodman, 1996). These tissues are valuable resources that can be 
maintained, accessed, and used without the knowledge of the donor (Nelkin & Andrews, 
1998). In a recent lawsuit filed against a researcher and a southern children=s hospital 
in the United States, families of Ashkenazi Jewish children who had died of a 
degenerative brain disease opposed a patent of the gene that causes the disease on 
the grounds that the researcher is profiting from the discovery and limiting access for 
the gene by charging for testing. Dr. J. Tsipis, a professor of biology at Brandeis 
University states that this incident is the ultimate nightmare of how a gene patent can be 
used against the very families who made possible the discovery of the gene@ 
(Associated Press, 2000, p. A-19). It is not clear if the participants or the families gave 
consent for research to develop a patented gene or if IRB approval was given for the 
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development of the patent. It is clear that many people do feel victimized when tissues 
are used in ways that were not originally consented for. In 1951, H. Lacks died of 
ovarian cancer. Her tissue was taken and used to develop a commercial cell line for 
research without consent. Even forty-three years later, her husband stated that he felt 
like both he and his wife were being exploited by researchers who were making a profit 
at their expense (Nelkin & Andrews, 1998). Legally it is not clear if it is necessary to 
disclose to the participants plans to develop genetic products for commercial gain. In a 
1990 legal case brought by Moore versus Regents of the University of California, the 
court ruled that the individual did not retain property interest in tissue that was used to 
develop a commercial product (Moore vs. Regents of the University of California 793 P. 
2d 479) (Reilly et al., 1997). Reilly and colleagues (1997) argue that ethically such 
disclosure is necessary under the principles of respect for persons and for the principles 
of informed consent.  
Informed Consent and Threat of Discrimination  
These cases open the door for a discussion of discrimination and stigmatization. 
Genetic data leads to the possibility of discrimination in employment or insurance 
coverage because of genetic markers for a disease and the possibility of further 
discrimination and stigmatization of a particular ethnic group based on genetic 
predisposition to a disease. Many people do not want their genetic information used to 
link a gene to a particular behavioral disorder, to identify a disease that occurs in a 
certain ethnic group, or in studies to link certain genes with IQ or stigmatizing social 
problems such as crime (Nelkin & Andrews, 1998). Genetic information has been used 
in the past to justify governments such as the United States, China, and Nazi Germany 
in their actions against people considered genetically inferior (Troy, 1997; Wikler, 1999). 
Mistrust of research endeavors is understandable from certain ethnic groups who have 
been discriminated against or whose rights have not been protected in previous 
research. 
Numerous recommendations and legislation have been proposed in an effort to protect 
people from harm related to the use and misuse of genetic material. Most of the 
documents to protect human subjects have focused on protection from physical harm. 
However, genetic information carries a risk for psychological harm, harm from 
discrimination and stigmatization, or economic and other social harm (Clayton, 1995; 
NCHGR-DOE, 1996; Reilly, 1997; Reilly, Boshar, & Holtzman, 1997). Guidelines for 
genetic data release were announced by DOE and NIH in 1992, and recommendations 
from ELSI on genetic and insurance information release were issued in 1993. The 
Genetic Privacy Act was passed in 1994 as the first United States legislation to regulate 
genome information. However, only DNA is controlled and other materials such as RNA 
from which genetic material can be removed are not regulated (Troy, 1997). The DOE 
and NCHGR issued guidelines to protect subjects in large scale sequencing studies in 
1996. The United Nations Educational, Scientific, and Cultural Organization (UNESCO) 
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adopted the Universal Declaration on the Human Genome and Human Rights in 1997 
(United Nations, 1998). 
Genetic discrimination in employment or insurance availability and coverage has been 
one of the major concerns in the Human Genome Project. The Equal Employment 
Opportunity Commission (EEOC) extended the Americans with Disabilities Act (ADA) 
employment protection to cover genetics information in 1995. The Health Insurance 
Portability and Accountability Act (HIPAA) was passed in 1996 prohibiting the use of 
genetic information in employer-based and commercially issued group health insurance 
eligibility decisions (U. S. Department of Energy [USDOE] Human Genome Program, 
2002). A predisposing gene for a disease is covered under the protection unless the 
person has already developed the disease prior to seeking health insurance (Reilly, 
1997). In 2000, President W. Clinton issued an executive order prohibiting federal 
departments or agencies from using genetic information in hiring or promoting 
employees. Currently, there are no federal laws specifically related to genetic 
discrimination in individual insurance coverage or discrimination in the workplace 
(USDOE Human Genome Program, 2002). Many states have passed laws to attempt to 
regulate access to genetic data and protect people (NIH, 1999). HUGO Ethics 
Committee and UNESCO recommend that no disclosure should be made to third 
parties to prevent discrimination (HUGO  
Ethics Committee, 1998; United Nations, 1998) unless compelled by law. Several 
authors (Reilly, 1997; Sass, 1998) suggest the use of Certificates of Confidentiality to 
prevent compelled disclosure. Without legal safeguards, the possibility exists that an 
individual will be pressured to give permission for access to genetic information to a 
third party such as an insurance company in order to receive coverage. In addition, if 
the third party really wants the genetic information, they may require a blood test such 
as is now required in many cases in order to receive health insurance. Once the blood 
test is given, genetic tests can be done (Rothstein, 1998). 
Many other ethical concerns in genetic research are related to informed consent. 
Genetic samples can be stored and used in the future for purposes not planned in the 
original research protocol. Many of the future uses or risks cannot be anticipated now 
because of the lack of knowledge of how the science will develop (NCHGR-DOE, 1996). 
In other words, geneticists do not fully understand what can be done with stored genetic 
samples because the tests and procedures haven=t been developed yet. The potential 
risks may be great but the benefits to the participant are usually not direct ones but are 
more altruists in nature (NCHGR-DOE, 1996; Reilly et al., 1997). Because of the ability 
to store information for long periods from which more research can be done, the 
potential use for commercial for-profit research, the possibility of breaches in privacy, 
the impact of genetic data on families, and the possibility of discrimination and 
stigmatization, participants must be given complete information to be able to make an 
informed decision about donating genetic tissues.  
Ethics and Genetic Privacy 
 
7 
Measures To Protect People From Harm 
Methods recommended to safeguard participants in research are the removal of all 
identifying links between the person and the sample in most cases, creating anonymous 
samples, or creating many disconnects between the sample and the individual to 
maintain confidentiality and privacy. Legal protection of data from third parties such as 
employers or insurance agencies even when the participant has given consent to 
release the information is needed (HUGO Ethics Committee, 1998; United Nations, 
1998). Completely informing participants of potential future uses of the DNA sample, 
whether it will be made anonymous or coded, who will have access, the risks and 
benefits, whether genetic information will be given to the participant, the lack of 
opportunity to withdraw data after it is made anonymous or becomes information in the 
public domain, and the potential risks to family or racial groups to which the donor may 
belong is necessary for informed consent in genetic studies (NCHGR-DOE, 1996). 
Institutional Review Boards must also review protocols carefully, recognizing the 
potential economic, social, and psychological risks involved. Under the Common Rule, 
human subject data includes not only the sample obtained through intervention but also 
includes data that is identifiable private information (Merz et al., 1999; Sugarman et al., 
1998). Thus all genetic research must undergo IRB approval.  
Conclusion 
With the increased knowledge of the human genome and the expanded interest in the 
potential for therapies and research that may improve health and reduce disease, 
comes the potential for harm. Several issues were presented using a deontological 
ethical view. Among these were respect for persons, autonomy, beneficence, non-
maleficence, privacy, confidentiality, and informed consent in which the person is clearly 
presented the present and possible future implications of genetic testing, therapies, and 
research. Methods to safeguard people included unlinking genetic material from the 
identifiers in most cases, and clear consents that specify how the sample will be used, 
who has access, and benefits and risks, including the potential risk of stigmatization or 
discrimination.  
All researchers have obligations to protect the privacy and confidentiality of participants, 
to assure that publications identifying a genetic difference in a particular group do not 
cause emotional distress or lead to a stigma being attached to a group, and to fully 
inform the public of the potential risks and benefits of donating DNA for sequencing and 
banking material so that an informed decision can be made. Scientists in the field of 
genetics have attempted to anticipate potential problems and make recommendations 
to protect human subjects participating in genetic research because of the unique 
nature of genetics. The articles adopted by the United Nations (United Nations, 1998) 
and the supplemental policies issued by the NCHGR-DOE for human subjects research 
in large-scale DNA sequencing studies (NCHGR-DOE, 1996) offer additional methods 
that attempt to safeguard human subjects. 
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